AstraZeneca : Un deal transformant qui dynamise encore le potentiel de croissance d’AZN
>OPA amicale sur le spécialiste des maladies rares Alexion - AstraZeneca a annoncé ce week-end une OPA amicale sur Alexion, spécialiste des maladies rares en immunologie, société de près de 5 Md$ de CA en 2019 et de 50% de marge d’EBITDA. L’opération, d’un total de 39,4 Md$ sera payée 1/3 en cash (60 $ par titre) et 2/3 en actions (2,1243 ADS AZN par titre). Finalement, le prix payé par AZN à 175 $ par action présente une prime de 45% sur le dernier cours d’Alexion. ...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.